Mass vaccination and drug administration for malaria in Bangladesh

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open, cluster-randomised, controlled intervention aims to evaluate the effectiveness of mass drug administrations and vaccinations against Plasmodium falciparum malaria. The study will enroll entire village populations and follow them for two years to compare malaria transmission rates between intervention and control villages. It will also assess the individual effectiveness of the vaccine and drug treatments. Participants will receive the DHA/piperaquine treatment and the R21/Matrix-M™ vaccine as part of the intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Current residence in a study village irrespective of permanence
* Age 6 months and above (no upper age limit)
* Written informed consent provided by participants (or a parent/guardian in case the participant is under 18 years old)

Exclusion Criteria:

* Pregnancy, plan to get pregnant, or breastfeeding.
* Acute illness requiring intervention
* A history of an adverse reaction to study drugs/vaccine and prior receipt of any other malaria vaccine or enrolment in another intervention trial.

Where it's running

• Alikadam Upazila Health Complex
  Bāndarban, Bangladesh Recruiting
• Lama Upazila Health Complex
  Lāma, Bangladesh Recruiting

Study contacts

• Principal investigator: Lorenz von Seidlein — Mahidol University
• Study coordinator: Lorenz von Seidlein
• Email: Lorenz@tropmedres.ac
• Phone: +66926486322

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• See if the R21/Matrix-M malaria vaccine works in real-world settings for kids under 5

  This study tests how well the R21/Matrix-M vaccine protects children under 5 in Burkina Faso and Uganda when used in typical clinical care.

  Recruiting at 12 sites Clinton Health Access Initiative Inc. · Boromo, Boucle Mouhoun and 20 other locations · NCT07749911

• Single-dose combination therapy for uncomplicated malaria in young children

  This study tests whether a single oral dose of a combination of anti-malarial drugs can cure uncomplicated Plasmodium falciparum malaria in children aged 2 to under 12 years, compared with standard Coartem treatment.

  Recruiting at 5 sites Phase 2 Novartis · Banfora and 12 other locations · NCT07811908

• Fixed-dose combination of artemether-lumefantrine-amodiaquine for uncomplicated falciparum malaria

  This trial will test whether a single fixed-dose combination of three antimalarials (artemether-lumefantrine-amodiaquine) works as well and is as safe and tolerable as standard two-drug combinations for people with uncomplicated Plasmodium falciparum malaria.

  Recruiting Phase 3 University of Oxford · Ruhuha, Eastern Province · NCT05951595

• Evaluating anti-malarial agents for uncomplicated malaria

  This study is testing different malaria medications to see how well they work and how safe they are for people with uncomplicated malaria.

  Recruiting at 12 sites Phase 2 Novartis · Banfora and 11 other locations · NCT05750628

• PfSPZ-LARC2 vaccine test in women of childbearing potential in Mali

  This trial tests whether the PfSPZ-LARC2 vaccine is safe and can help protect healthy women of childbearing potential in Mali from malaria.

  Recruiting Phase 2 Sanaria Inc. · Bamako · NCT07675785

• Imatinib added to artemether-lumefantrine for uncomplicated P. falciparum malaria

  This trial tests whether adding imatinib to standard artemether-lumefantrine helps people with uncomplicated Plasmodium falciparum malaria clear infections faster and limit drug-resistant parasites.

  Recruiting Phase 2 Victoria Biomedical Research Institute · Kisumu · NCT07559370

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.